AU2004245038A1 - De-immunized anti-CD3 antibody - Google Patents

De-immunized anti-CD3 antibody Download PDF

Info

Publication number
AU2004245038A1
AU2004245038A1 AU2004245038A AU2004245038A AU2004245038A1 AU 2004245038 A1 AU2004245038 A1 AU 2004245038A1 AU 2004245038 A AU2004245038 A AU 2004245038A AU 2004245038 A AU2004245038 A AU 2004245038A AU 2004245038 A1 AU2004245038 A1 AU 2004245038A1
Authority
AU
Australia
Prior art keywords
antibody
immunized
chain variable
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004245038A
Other languages
English (en)
Inventor
Francis J. Carr
Susan Faas-Knight
Anita Hamilton
Russell P. Rother
Dayang Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2004245038A1 publication Critical patent/AU2004245038A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004245038A 2003-06-02 2004-05-28 De-immunized anti-CD3 antibody Abandoned AU2004245038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47515503P 2003-06-02 2003-06-02
US60/475,155 2003-06-02
PCT/US2004/017219 WO2004108158A1 (en) 2003-06-02 2004-05-28 De-immunized anti-cd3 antibody

Publications (1)

Publication Number Publication Date
AU2004245038A1 true AU2004245038A1 (en) 2004-12-16

Family

ID=33511652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004245038A Abandoned AU2004245038A1 (en) 2003-06-02 2004-05-28 De-immunized anti-CD3 antibody

Country Status (7)

Country Link
US (1) US20070292416A1 (enExample)
EP (1) EP1658095A4 (enExample)
JP (1) JP2006526414A (enExample)
CN (1) CN1822857A (enExample)
AU (1) AU2004245038A1 (enExample)
CA (1) CA2527726A1 (enExample)
WO (1) WO2004108158A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
EP2463305B1 (en) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
US8530629B2 (en) * 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
IN2012DN04412A (enExample) 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
TW201244737A (en) 2011-02-03 2012-11-16 Alexion Pharma Inc Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
JP2015504413A (ja) 2011-10-28 2015-02-12 パトリス リミテッド Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
CN105979965B (zh) 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
AU2015336931B2 (en) 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
ES2717308T3 (es) 2014-12-06 2019-06-20 Gemoab Monoclonals Gmbh Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
JP7095992B2 (ja) 2014-12-08 2022-07-05 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
KR102755742B1 (ko) 2017-09-11 2025-01-15 모나쉬 유니버시티 인간 트롬빈 수용체 par4 결합 단백질
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
CN121591910A (zh) * 2017-11-21 2026-03-03 诺华股份有限公司 针对肿瘤相关抗原的三特异性结合分子及其用途
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019114768A1 (en) 2017-12-12 2019-06-20 Biocytogen Jiangsu Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
CN112118859A (zh) 2018-05-16 2020-12-22 杰特有限公司 1型可溶性补体受体变体及其用途
MX2021000239A (es) 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
CN114502583A (zh) 2019-08-12 2022-05-13 杰特创新股份有限公司 补体c2结合蛋白及其用途
JP7807372B2 (ja) 2019-12-20 2026-01-27 ハドソン インスティチュート オブ メディカル リサーチ Ｃｘｃｌ１０結合タンパク質及びその使用
WO2021195513A1 (en) * 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
EP4581055A1 (en) 2022-08-31 2025-07-09 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
JP4279554B2 (ja) * 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法

Also Published As

Publication number Publication date
EP1658095A1 (en) 2006-05-24
WO2004108158A1 (en) 2004-12-16
CA2527726A1 (en) 2004-12-16
US20070292416A1 (en) 2007-12-20
JP2006526414A (ja) 2006-11-24
EP1658095A4 (en) 2006-06-14
CN1822857A (zh) 2006-08-23

Similar Documents

Publication Publication Date Title
US20070292416A1 (en) De-Immunized Anti-Cd3 Antibody
EP1383785B1 (en) Recombinant tumor specific antibody and use thereof
EP4582449A1 (en) Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof
JP3653093B2 (ja) 人化抗体
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
CN106046159B (zh) Cd37结合分子及其免疫缀合物
US7332582B2 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US20170335016A1 (en) Stable multivalent antibody
CN111349163B (zh) 针对cd123的单克隆抗体
CN112500485B (zh) 一种抗b7-h3抗体及其应用
CN115087673A (zh) 结合il4r的抗体及其用途
TW202246340A (zh) 抗ctla-4抗體及其應用
CN118510805A (zh) 一种gprc5d抗体及其应用
KR20230166096A (ko) Cldn18.2 항원 결합 단백질 및 이의 적용
CN118667003A (zh) 特异性结合Claudin18.2的抗体及其制法和应用
EP3778632A1 (en) Anti-human lag-3 monoclonal antibody and use thereof
EP4406970A1 (en) Monoclonal antibody targeting tigit
MXPA06009759A (es) Codocito para trastornos por linfocitos b.
CN114478788B (zh) 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
CN118556082A (zh) p95HER2抗体及其应用
WO2001023431A1 (fr) Derives d'anticorps contre le ganglioside gm2
JP2005333993A (ja) 新規なダイアボディ型二重特異性抗体
EP4219553A1 (en) Anti-tigit antibody and double antibody and their application
HK40089099A (en) Anti-tigit antibody and double antibody and their application

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application